Company / Cash & Equivalents
Altimmune, Inc. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$43.8M
FY2025
5-year range
$36.9M / $190.3M
FY2021-FY2025
Trend
+18.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $3M in FY2011 to $190M in FY2021.
Based on SEC 10-K filings.
$44M in FY2025 with a 5-year CAGR of -17.7%.
Declined from $135M to $44M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -26.7%
- 5-Year CAGR
- -17.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -17.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 18.5% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2011.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.8M | +18.5% |
| FY2024 | $36.9M | -72.7% |
| FY2023 | $135.1M | +21.6% |
| FY2022 | $111.1M | -41.6% |
| FY2021 | $190.3M | +64.2% |
| FY2020 | $115.9M | +1193.3% |
| FY2019 | $9.0M | -73.4% |
| FY2018 | $33.7M | +284.5% |
| FY2017 | $8.8M | +228.0% |
| FY2011 | $2.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026